Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.57 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | NQO2 | P16083 | 2/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163586 | 1.00 | RELA (0.70) | RELAMAPTSMN1; SMN2ALDH1A1GLA | |
| SCHEMBL18381453 | 0.92 | NPC1 (0.57) | RELAMAPTSMN1; SMN2ALDH1A1GLA | |
| SCHEMBL30872347 | 0.88 | NPC1 (0.53) | RELAMAPTSMN1; SMN2ALDH1A1GLA | |
| SCHEMBL29842519 | 0.85 | RELA (0.86) | RELAMAPTSMN1; SMN2ALDH1A1GLA | |
| SCHEMBL5050698 | 0.85 | RELA (0.86) | RELAMAPTSMN1; SMN2ALDH1A1GLA | |
| SCHEMBL5050695 | 0.85 | RELA (0.86) | RELAMAPTSMN1; SMN2ALDH1A1GLA | |
| SCHEMBL5552166 | 0.85 | RELA (0.86) | RELAMAPTSMN1; SMN2ALDH1A1GLA | |
| SCHEMBL5552162 | 0.85 | RELA (0.86) | RELAMAPTSMN1; SMN2ALDH1A1GLA | |
| SCHEMBL4800219 | 0.84 | CYP1A1 (0.49) | RELAMAPTSMN1; SMN2ALDH1A1GLA | |
| SCHEMBL5407847 | 0.83 | RELA (1.00) | RELAMAPTSMN1; SMN2ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | NANOEGG RESEARCH LABORATORIES, INC. (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3456353-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | Nanoegg Research Laboratories, Inc. (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-8158380-B2 | Imaging agents for protein misfolding | NEW YORK UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158380-B2 | Imaging agents for protein misfolding | NEW YORK UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100279340-A1 | Imaging agents for protein misfolding | NYU (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279340-A1 | Imaging agents for protein misfolding | NYU (US) | 2010-11-04 | — | — | US | disclosed |
| US-6846830-B2 | Naphtalene derivatives and their pharmaceutical use | ELI LILLY AND COMPANY (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030073725-A1 | Naphtalene derivatives and their pharmaceutical use | ELI LILLY AND COMPANY | 2003-04-17 | — | — | US | disclosed |
| EP-1138328-A1 | Naphthalene derivatives as CNS drugs | ELI LILLY AND COMPANY LIMITED (GB) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | CHRM3, ACHE, CHRNB1 | RELA 1180/4885MAPT 313/4885SMN1; SMN2 4378/4885 |
| US-20100279340-A1 | Imaging agents for protein misfolding | APBA1, APP, SPG11 | RELA 2359/4885MAPT 4/4885SMN1; SMN2 1019/4885 |
| US-20030073725-A1 | Naphtalene derivatives and their pharmaceutical use | CHRNA6, ATP6V1B2, GRM6 | RELA 1688/4885MAPT 2452/4885SMN1; SMN2 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.